ironwood pharmaceuticals

Ironwood, AstraZeneca Initiate Linaclotide PhIII Trial In China

Ironwood and AstraZeneca have initiated a Phase III clinical trial of linaclotide for the treatment of adults with irritable bowel syndrome with constipation.

Ironwood, AstraZeneca To Develop Linaclotide In China

AstraZeneca and Ironwood Pharmaceuticals, Inc. announced this week an agreement to co‐develop and co‐commercialize Ironwood’s linaclotide in China.